Hepatology
Conference Coverage
Resmetirom reduces liver, CV risk factors in NASH with cirrhosis
“I do think it could be one of the drugs that really improves outcomes for patients with NASH.”
Conference Coverage
Noninvasive tests may provide prognostic value in NAFLD
Fibrosis biomarkers were significantly predictive of event-free survival probability.
Conference Coverage
Low-carb diet aids weight loss in liver transplant recipients with obesity
The diet didn’t negatively affect serum lipids or renal function.
News
FDA rejects bulevirtide for hepatitis D
The FDA cited concerns over the production and delivery of bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor...
Conference Coverage
NAFLD progresses to cirrhosis in young and old at similar rate
Risk factors for NAFLD vary with age, but all patients experience similar progression of advanced disease once it develops.
From the Journals
COVID tied to spike in deaths in chronic liver disease with diabetes
“Our observations confirm that COVID-19 had a higher likelihood of impacting vulnerable populations with pre-existing chronic liver diseases and...
Guidelines
New AGA guidelines advise use of antiobesity medications for weight management
Though lifestyle interventions are the first-line treatment for overweight and obesity, use of specific pharmacological agents should be...
From the Journals
Mentorship key to improving GI, hepatology workforce diversity
A collaboration of five gastroenterology and hepatology medical organizations presented findings on workforce perspectives on diversity and how to...
News
FDA okays terlipressin (Terlivaz) injection for hepatorenal syndrome
The synthetic vasopressin analog is an injectable medication indicated for patients with hepatorenal syndrome experiencing rapid deterioration of...
From the Journals
Hep C, HIV coinfection tied to higher MI risk with age
“Clinicians providing health care to people with HIV should know their patients’ HCV status and provide support regarding HCV treatment and ways...
From the Journals
New liver stiffness thresholds refine NASH risk stratification
These new thresholds are based on high-quality prospective data drawn from four randomized controlled trials.